Published in Adv Chronic Kidney Dis on March 01, 2010
Metabolomics in the study of kidney diseases. Nat Rev Nephrol (2011) 1.32
Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens (2010) 1.22
Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant (2011) 1.00
Vascular complications in autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2015) 0.84
Current management of autosomal dominant polycystic kidney disease. World J Nephrol (2015) 0.82
Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry. BMC Nephrol (2013) 0.80
Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol (2013) 0.78
Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014). Popul Health Metr (2017) 0.78
Autosomal dominant polycystic kidney disease with ectopic unilateral multicystic dysplastic kidney. BMC Nephrol (2013) 0.77
Embolization of renal arteries before transplantation in patients with polycystic kidney disease: a single institution long-term experience. Eur Radiol (2015) 0.76
Maximal kidney length predicts need for native nephrectomy in ADPKD patients undergoing renal transplantation. Can Urol Assoc J (2014) 0.75
Ouabain Enhances ADPKD Cell Apoptosis via the Intrinsic Pathway. Front Physiol (2016) 0.75
End-Stage Kidney Failure in Oman: An Analysis of Registry Data with an Emphasis on Congenital and Inherited Renal Diseases. Int J Nephrol (2017) 0.75
Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy. Clinicoecon Outcomes Res (2017) 0.75
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med (2003) 23.33
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2011) 1.47
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int (2005) 1.02
The regulation of cystogenesis in a tissue engineered kidney disease system by abnormal matrix interactions. Biomaterials (2012) 0.81
Hypertension in individuals at risk for autosomal dominant polycystic kidney disease: to screen or not to screen? Am J Kidney Dis (2005) 0.80
mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med (2011) 0.79
Managing cyst infections in ADPKD: an old problem looking for new answers. Clin J Am Soc Nephrol (2009) 0.78
Left ventricular hypertrophy in ADPKD: changing demographics. Curr Hypertens Rev (2013) 0.77
Living donor transplantation: should we advocate for it? Nephrol News Issues (2014) 0.75
Erratum. Nephrol Dial Transplant (2017) 0.75
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol (2017) 0.75
Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops. Transplantation (2017) 0.75